Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma

Summary

The WHO and select biopharma companies are increasing focus on preeclampsia, a pregnancy-related hypertension disorder affecting millions of mothers and newborns annually. This represents a shift in attention toward a previously underserved therapeutic area.